Back to Search
Start Over
Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy‐Naive Metastatic Castrate‐Resistant Prostate Cancer.
- Source :
- Oncologist; Sep2019, Vol. 24 Issue 9, p1149-1149, 1p, 1 Diagram, 14 Charts, 2 Graphs
- Publication Year :
- 2019
-
Abstract
- <i>Copyright of Oncologist is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
- Subjects :
- PROTEIN-tyrosine kinase inhibitors
BIOMARKERS
CANCER chemotherapy
COMBINATION drug therapy
INTERLEUKINS
INTRAVENOUS therapy
MEDICAL cooperation
METASTASIS
NEUTROPENIA
PREDNISONE
PROSTATE tumors
RESEARCH
DOCETAXEL
PROSTATE-specific antigen
RANDOMIZED controlled trials
TREATMENT effectiveness
DISEASE progression
THERAPEUTICS
Subjects
Details
- Language :
- English
- ISSN :
- 10837159
- Volume :
- 24
- Issue :
- 9
- Database :
- Complementary Index
- Journal :
- Oncologist
- Publication Type :
- Academic Journal
- Accession number :
- 138543113
- Full Text :
- https://doi.org/10.1634/theoncologist.2019-0331